Human challenge models: tools to accelerate the development of malaria vaccines

References

• WHO. World malaria report 2017; [cited 2018 Nov 20]. Available from: https://www.who.int/malaria/publications/world-malaria-report-2017/en/
   Google Scholar
• Thu AM, Phyo AP, Landier J, et al. Combating multidrug-resistant Plasmodium falciparum malaria. FEBS J. 2017;284(16):2569–2578.
   PubMed Web of Science ®Google Scholar
• Moorthy VS, Newman RD, Okwo-Bele JM. Malaria vaccine technology roadmap. Lancet. 2013;382(9906):1700–1701.
   PubMed Web of Science ®Google Scholar
• Doolan DL, Dobano C, Baird JK. Acquired immunity to malaria. Clin Microbiol Rev. 2009;22(1):13–36.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Mosquirix H-W-2300; [ cited 2018 Nov 20]. Available from: https://www.ema.europa.eu/mosquirix-h-w-2300
   Google Scholar
• RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015;386(9988):31–45.
   PubMed Web of Science ®Google Scholar
• Sauerwein RW, Roestenberg M, Moorthy VS. Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol. 2011;11(1):57–64.
   PubMed Web of Science ®Google Scholar
• HIC-Vac. Workshop News: Accelerating vaccine development in the UK safely: enhancing Human Challenge Studies to combat infectious diseases; [ cited 13 Nov 2018]. Available from: https://www.hic-vac.org/news/workshop-news-safely-enhancing-human-challenge
   Google Scholar
• Collins WE, Jeffery GM. A retrospective examination of the patterns of recrudescence in patients infected with Plasmodium falciparum. Am J Trop Med Hyg. 1999;61(1):44–48.
   PubMed Web of Science ®Google Scholar
• Collins WE, Jeffery GM. A retrospective examination of sporozoite- and trophozoite-induced infections with Plasmodium falciparum: development of parasitologic and clinical immunity during primary infection. Am J Trop Med Hyg. 1999;61(1):4–19.
   PubMed Web of Science ®Google Scholar
• Collins WE, Jeffery GM. A retrospective examination of sporozoite- and trophozoite-induced infections with Plasmodium falciparum in patients previously infected with heterologous species of Plasmodium: effect on development of parasitologic and clinical immunity. Am J Trop Med Hyg. 1999;61(1):36–43.
   PubMed Web of Science ®Google Scholar
• Collins WE, Jeffery GM. A retrospective examination of secondary sporozoite- and trophozoite-induced infections with Plasmodium falciparum: development of parasitologic and clinical immunity following secondary infection. Am J Trop Med Hyg. 1999;61(1):20–35.
   PubMed Web of Science ®Google Scholar
• Clyde DF, Most H, McCarthy VC, et al. Immunization of man against sporozite-induced falciparum malaria. Am J Med Sci. 1973;266(3):169–177.
   PubMed Web of Science ®Google Scholar
• Rieckmann KH, Carson PE, Beaudoin RL, et al. Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum. Trans R Soc Trop Med Hyg. 1974;68(3):258–259.
   PubMed Web of Science ®Google Scholar
• Trager W, Jensen JB. Human malaria parasites in continuous culture. Science. 1976;193(4254):673–675.
   PubMed Web of Science ®Google Scholar
• Chulay JD, Schneider I, Cosgriff TM, et al. Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum. Am J Trop Med Hyg. 1986;35(1):66–68.
   PubMed Web of Science ®Google Scholar
• Vanderberg JV, Gwadz RW, Kreier J. The transmission by mosquitoes of plasmodia in the laboratory. Malaria. 1980;2:180–181.
   Google Scholar
• Roestenberg M, Mordmuller B, Ockenhouse C, et al. The frontline of controlled human malaria infections: A report from the controlled human infection models workshop in Leiden University medical centre 5 May 2016. Vaccine. 2017;35(51):7065–7069.
   PubMed Web of Science ®Google Scholar
• Hoffman SL, Goh LM, Luke TC, et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis. 2002;185(8):1155–1164.
   PubMed Web of Science ®Google Scholar
• Roestenberg M, Bijker EM, Sim BK, et al. Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg. 2013;88(1):5–13.
   PubMed Web of Science ®Google Scholar
• Gomez-Perez GP, Legarda A, Munoz J, et al. Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved Plasmodium falciparum sporozoites in malaria-naive volunteers: effect of injection volume and dose on infectivity rates. Malar J. 2015;14:306.
   PubMed Web of Science ®Google Scholar
• Richie TL, Billingsley PF, Sim BK, et al. Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines. Vaccine. 2015;33(52):7452–7461.
   PubMed Web of Science ®Google Scholar
• Cheng Q, Lawrence G, Reed C, et al. Measurement of Plasmodium falciparum growth rates in vivo: a test of malaria vaccines. Am J Trop Med Hyg. 1997;57(4):495–500.
   PubMed Web of Science ®Google Scholar
• Pombo DJ, Lawrence G, Hirunpetcharat C, et al. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet. 2002;360(9333):610–617.
   PubMed Web of Science ®Google Scholar
• Stanisic DI, McCarthy JS, Good MF. Controlled human malaria infection: applications, advances, and challenges. Infect Immun. 2018;86(1):e00479–17.
   PubMed Web of Science ®Google Scholar
• McCarthy JS, Smith B, Reid M, et al. Blood schizonticidal activity and safety of tafenoquine when administered as chemoprophylaxis to healthy, non-immune participants followed by blood stage Plasmodium falciparum challenge: A randomized, double-blinded, placebo-controlled Phase 1b study. Clin Infect Dis. 2018.
   Google Scholar
• Burel JG, Apte SH, Groves PL, et al. Reduced Plasmodium parasite burden associates with CD38+ CD4+ T cells displaying cytolytic potential and impaired IFN-gamma production. PLOS Pathog. 2016;12(9):e1005839.
   PubMed Web of Science ®Google Scholar
• Edwards CL, Ng SS, Corvino D, et al. Early changes in CD4+ T-cell activation during blood-stage Plasmodium falciparum infection. J Infect Dis. 2018;218(7):1119–1129.
   PubMed Web of Science ®Google Scholar
• Bijker EM, Bastiaens GJ, Teirlinck AC, et al. Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity. Proc Natl Acad Sci USA. 2013;110(19):7862–7867.
   PubMed Web of Science ®Google Scholar
• Trieu A, Kayala MA, Burk C, et al. Sterile protective immunity to malaria is associated with a panel of novel P. falciparum antigens. Mol Cell Proteomics. 2011;10(9):M111.007948.
   Web of Science ®Google Scholar
• Teirlinck AC, Roestenberg M, van de Vegte-Bolmer M, et al. NF135.C10: a new Plasmodium falciparum clone for controlled human malaria infections. J Infect Dis. 2013;207(4):656–660.
   PubMed Web of Science ®Google Scholar
• Payne RO, Griffin PM, McCarthy JS, et al. Plasmodium vivax controlled human malaria infection - progress and prospects. Trends Parasitol. 2017;33(2):141–150.
   PubMed Web of Science ®Google Scholar
• McCarthy JS, Griffin PM, Sekuloski S, et al. Experimentally induced blood-stage Plasmodium vivax infection in healthy volunteers. J Infect Dis. 2013;208(10):1688–1694.
   PubMed Web of Science ®Google Scholar
• Collins KA, Wang CY, Adams M, et al. A controlled human malaria infection model enabling evaluation of transmission-blocking interventions. J Clin Invest. 2018;128(4):1551–1562.
   PubMed Web of Science ®Google Scholar
• Hodgson SH, Juma E, Salim A, et al. Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection. Front Microbiol. 2014;5:686.
   PubMed Web of Science ®Google Scholar
• Hill AV. Vaccines against malaria. Philos Trans R Soc Lond B Biol Sci. 2011;366(1579):2806–2814.
   PubMed Web of Science ®Google Scholar
• Duncan CJ, Draper SJ. Controlled human blood stage malaria infection: current status and potential applications. Am J Trop Med Hyg. 2012;86(4):561–565.
   PubMed Web of Science ®Google Scholar
• Herrington DA, Clyde DF, Murphy JR, et al. do Rosario V, et al. A model for Plasmodium falciparum sporozoite challenge and very early therapy of parasitaemia for efficacy studies of sporozoite vaccines. Trop Geogr Med. 1988;40(2):124–127.
   PubMedGoogle Scholar
• Douglas AD, Edwards NJ, Duncan CJ, et al. Comparison of modeling methods to determine liver-to-blood inocula and parasite multiplication rates during controlled human malaria infection. J Infect Dis. 2013;208(2):340–345.
   PubMed Web of Science ®Google Scholar
• Pawliw R, Farrow R, Sekuloski S, et al. A bioreactor system for the manufacture of a genetically modified Plasmodium falciparum blood stage malaria cell bank for use in a clinical trial. Malar J. 2018;17(1):283.
   PubMedGoogle Scholar
• Laurens MB, Duncan CJ, Epstein JE, et al. A consultation on the optimization of controlled human malaria infection by mosquito bite for evaluation of candidate malaria vaccines. Vaccine. 2012;30(36):5302–5304.
   PubMedGoogle Scholar
• Laurens MB, Billingsley P, Richman A, et al. Successful human infection with P. falciparum using three aseptic Anopheles stephensi mosquitoes: a new model for controlled human malaria infection. PLoS One. 2013;8(7).
   Web of Science ®Google Scholar
• Hollingdale MR, Sedegah M. Development of whole sporozoite malaria vaccines. Expert Rev Vaccines. 2017;16(1):45–54.
   PubMed Web of Science ®Google Scholar
• Sanderson F, Andrews L, Douglas AD, et al. Blood-stage challenge for malaria vaccine efficacy trials: a pilot study with discussion of safety and potential value. Am J Trop Med Hyg. 2008;78(6):878–883.
   PubMed Web of Science ®Google Scholar
• Duncan CJ, Sheehy SH, Ewer KJ, et al. Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909. PLoS One. 2011;6(7):e22271.
   PubMed Web of Science ®Google Scholar
• McCarthy JS, Sekuloski S, Griffin PM, et al. A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs. PLOS ONE. 2011;6(8):e21914.
   PubMed Web of Science ®Google Scholar
• Lawrence G, Cheng QQ, Reed C, et al. Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers. Vaccine. 2000;18(18):1925–1931.
   PubMed Web of Science ®Google Scholar
• Spence PJ, Brugat T, Langhorne J, et al. Mosquitoes Reset Malaria Parasites. PLOS Pathog. 2015;11(7):e1004987.
   PubMed Web of Science ®Google Scholar
• Peters J, Fowler E, Gatton M, et al. High diversity and rapid changeover of expressed var genes during the acute phase of Plasmodium falciparum infections in human volunteers. Proc Natl Acad Sci U S A. 2002;99(16):10689–10694.
   PubMed Web of Science ®Google Scholar
• Sinden RE. Developing transmission-blocking strategies for malaria control. PLOS Pathog. 2017;13(7):e1006336.
   PubMed Web of Science ®Google Scholar
• Pasay CJ, Rockett R, Sekuloski S, et al. Piperaquine monotherapy of drug-susceptible Plasmodium falciparum infection results in rapid clearance of parasitemia but is followed by the appearance of gametocytemia. J Infect Dis. 2016;214(1):105–113.
   PubMed Web of Science ®Google Scholar
• Payne RO, Milne KH, Elias SC, et al. Demonstration of the blood-stage Plasmodium falciparum controlled human malaria infection model to assess efficacy of the P. falciparum apical membrane antigen 1 vaccine, FMP2.1/AS01. J Infect Dis. 2016;213(11):1743–1751.
   PubMed Web of Science ®Google Scholar
• Moormann AM, Stewart VA. The hunt for protective correlates of immunity to Plasmodium falciparum malaria. BMC Med. 2014;12:134.
   PubMed Web of Science ®Google Scholar
• Bejon P, Andrews L, Andersen RF, et al. Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. J Infect Dis. 2005;191(4):619–626.
   PubMed Web of Science ®Google Scholar
• Hermsen CC, de Vlas SJ, van Gemert GJ, et al. Testing vaccines in human experimental malaria: statistical analysis of parasitemia measured by a quantitative real-time polymerase chain reaction. Am J Trop Med Hyg. 2004;71(2):196–201.
   PubMed Web of Science ®Google Scholar
• Montes de Oca M, Kumar R, Rivera FL, et al. Type I interferons regulate immune responses in humans with blood-stage Plasmodium falciparum infection. Cell Rep. 2016;17(2):399–412.
   PubMed Web of Science ®Google Scholar
• Burel JG, Apte SH, McCarthy JS, et al. Plasmodium vivax but not Plasmodium falciparum blood-stage infection in humans is associated with the expansion of a CD8+ T cell population with cytotoxic potential. PLoS Negl Trop Dis. 2016;10(12):e0005031.
   PubMed Web of Science ®Google Scholar
• Wockner LF, Hoffmann I, O’Rourke P, et al. Comparison of statistical models to estimate parasite growth rate in the induced blood stage malaria model. Malar J. 2017;16(1):352.
   PubMedGoogle Scholar
• Simpson JA, Aarons L, Collins WE, et al. Population dynamics of untreated Plasmodium falciparum malaria within the adult human host during the expansion phase of the infection. Parasitology. 2002;124(Pt 3):247–263.
   PubMedGoogle Scholar
• Coffeng LE, Hermsen CC, Sauerwein RW, et al. The power of malaria vaccine trials using controlled human malaria infection. PLoS Comput Biol. 2017;13(1):e1005255.
   PubMed Web of Science ®Google Scholar
• Ouattara A, Barry AE, Dutta S, et al. Designing malaria vaccines to circumvent antigen variability. Vaccine. 2015;33(52):7506–7512.
   PubMed Web of Science ®Google Scholar
• MalariaGen Genomic Epidemiology Network; [ cited 2019 Feb 1]. Available from: https://www.malariagen.net
   Google Scholar
• Barry AE, Arnott A. Strategies for designing and monitoring malaria vaccines targeting diverse antigens. Front Immunol. 2014;5:359.
   PubMed Web of Science ®Google Scholar
• Barry AE, Schultz L, Buckee CO, et al. Contrasting population structures of the genes encoding ten leading vaccine-candidate antigens of the human malaria parasite, Plasmodium falciparum. PLoS One. 2009;4(12):e8497.
   PubMed Web of Science ®Google Scholar
• Pringle JC, Carpi G, Almagro-Garcia J, et al. RTS,S/AS01 malaria vaccine mismatch observed among Plasmodium falciparum isolates from southern and central Africa and globally. Sci Rep. 2018;8(1):6622.
   PubMedGoogle Scholar
• Neafsey DE, Juraska M, Bedford T, et al. Genetic diversity and protective efficacy of the RTS,S/AS01 malaria vaccine. N Engl J Med. 2015;373(21):2025–2037.
   PubMed Web of Science ®Google Scholar
• Gardner MJ, Hall N, Fung E, et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature. 2002;419(6906):498–511.
   PubMed Web of Science ®Google Scholar
• Le Roch KG, Zhou Y, Blair PL, et al. Discovery of gene function by expression profiling of the malaria parasite life cycle. Science. 2003;301(5639):1503–1508.
   PubMed Web of Science ®Google Scholar
• Florens L, Washburn MP, Raine JD, et al. A proteomic view of the Plasmodium falciparum life cycle. Nature. 2002;419(6906):520–526.
   PubMed Web of Science ®Google Scholar
• Waitumbi JN, Anyona SB, Hunja CW, et al. Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial. PLoS One. 2009;4(11):e7849.
   PubMed Web of Science ®Google Scholar
• Angov E, Aufiero BM, Turgeon AM, et al. Development and pre-clinical analysis of a Plasmodium falciparum merozoite surface protein-1(42) malaria vaccine. Mol Biochem Parasitol. 2003;128(2):195–204.
   PubMed Web of Science ®Google Scholar
• Payne RO, Silk SE, Elias SC, et al. Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions. JCI Insight. 2017;2(21):96381.
   PubMed Web of Science ®Google Scholar
• Wang R, Doolan DL, Le TP, et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science. 1998;282(5388):476–480.
   PubMed Web of Science ®Google Scholar
• Lyke KE, Ishizuka AS, Berry AA, et al. Attenuated PfSPZ vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. Proc Natl Acad Sci U S A. 2017;114(10):2711–2716.
   PubMed Web of Science ®Google Scholar
• Church LW, Le TP, Bryan JP, et al. Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge. J Infect Dis. 1997;175(4):915–920.
   PubMed Web of Science ®Google Scholar
• Mbb M, Wammes LJ, Langenberg MCC, et al. Infectivity of Plasmodium falciparum sporozoites determines emerging parasitemia in infected volunteers. Sci Transl Med. 2017;9(395):eaag2490.
   PubMed Web of Science ®Google Scholar
• Walk J, Reuling IJ, Behet MC, et al. Modest heterologous protection after Plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial. BMC Med. 2017;15(1):168.
   PubMedGoogle Scholar
• Schats R, Bijker EM, van Gemert GJ, et al. Heterologous protection against malaria after immunization with Plasmodium falciparum sporozoites. PLoS One. 2015;10(5):e0124243.
   PubMed Web of Science ®Google Scholar
• Stanisic DI, Liu XQ, De SL, et al. Development of cultured Plasmodium falciparum blood-stage malaria cell banks for early phase in vivo clinical trial assessment of anti-malaria drugs and vaccines. Malar J. 2015;14:143.
   PubMed Web of Science ®Google Scholar
• Stanisic DI, Gerrard J, Fink J, et al. Infectivity of Plasmodium falciparum in malaria-naive individuals is related to knob expression and cytoadherence of the parasite. Infect Immun. 2016;84(9):2689–2696.
   PubMed Web of Science ®Google Scholar
• Price RN, Tjitra E, Guerra CA, et al. Vivax malaria: neglected and not benign. Am J Trop Med Hyg. 2007;77(6):79–87.
   PubMed Web of Science ®Google Scholar
• Herrera S, Fernandez O, Manzano MR, et al. Successful sporozoite challenge model in human volunteers with Plasmodium vivax strain derived from human donors. Am J Trop Med Hyg. 2009;81(5):740–746.
   PubMed Web of Science ®Google Scholar
• Bennett JW, Pybus BS, Yadava A, et al. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N Engl J Med. 2013;369(14):1381–1382.
   PubMed Web of Science ®Google Scholar
• Bousema T, Drakeley C. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin Microbiol Rev. 2011;24(2):377–410.
   PubMed Web of Science ®Google Scholar
• Herrera S, Solarte Y, Jordan-Villegas A, et al. Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers. Am J Trop Med Hyg. 2011;84(2 Suppl):4–11.
   PubMed Web of Science ®Google Scholar
• Arevalo-Herrera M, Forero-Pena DA, Rubiano K, et al. Plasmodium vivax sporozoite challenge in malaria-naive and semi-immune Colombian volunteers. PLoS One. 2014;9(6):e99754.
   PubMed Web of Science ®Google Scholar
• Clyde DF. Immunity to falciparum and vivax malaria induced by irradiated sporozoites: a review of the University of Maryland studies, 1971–75. Bull World Health Organ. 1990;68:9–12.
   PubMed Web of Science ®Google Scholar
• Arevalo-Herrera M, Vasquez-Jimenez JM, Lopez-Perez M, et al. Protective efficacy of Plasmodium vivax radiation-attenuated sporozoites in colombian volunteers: a randomized controlled trial. PLoS Negl Trop Dis. 2016;10(10):e0005070.
   PubMed Web of Science ®Google Scholar
• Bennett JW, Yadava A, Tosh D, et al. Phase 1/2a trial of Plasmodium vivax malaria vaccine candidate VMP001/AS01B in malaria-naive adults: safety, immunogenicity, and efficacy. PLoS Negl Trop Dis. 2016;10(2).
   Web of Science ®Google Scholar
• Griffin P, Pasay C, Elliott S, et al. Safety and reproducibility of a clinical trial system using induced blood stage Plasmodium vivax infection and its potential as a model to evaluate malaria transmission. PLoS Negl Trop Dis. 2016;10(12):1688–1694.
   Web of Science ®Google Scholar
• Grigg MJ, William T, Barber BE, et al. Artemether-lumefantrine versus chloroquine for the treatment of uncomplicated Plasmodium knowlesi malaria: an open-label randomized controlled trial CAN KNOW. Clin Infect Dis. 2018;66(2):229–236.
   PubMed Web of Science ®Google Scholar
• Shekalaghe S, Rutaihwa M, Billingsley PF, et al. Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg. 2014;91(3):471–480.
   PubMed Web of Science ®Google Scholar
• Hodgson SH, Llewellyn D, Silk SE, et al. Changes in serological immunology measures in UK and Kenyan adults post-controlled human malaria infection. Front Microbiol. 2016;7:1604.
   PubMed Web of Science ®Google Scholar
• Hodgson SH, Juma E, Salim A, et al. Lessons learnt from the first controlled human malaria infection study conducted in Nairobi, Kenya. Malar J. 2015;14:182.
   PubMed Web of Science ®Google Scholar
• Jongo SA, Shekalaghe SA, Church LWP, et al. Safety, immunogenicity, and protective efficacy against controlled human malaria infection of Plasmodium falciparum sporozoite vaccine in Tanzanian adults. Am J Trop Med Hyg. 2018;99(2):338–349.
   PubMed Web of Science ®Google Scholar
• Zenklusen I, Jongo S, Abdulla S, et al. Immunization of malaria-preexposed volunteers with PfSPZ vaccine elicits long-lived IgM invasion-inhibitory and complement-fixing antibodies. J Infect Dis. 2018;217(10):1569–1578.
   PubMed Web of Science ®Google Scholar
• Sissoko MS, Healy SA, Katile A, et al. Safety and efficacy of PfSPZ vaccine against plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. Lancet Infect Dis. 2017;17(5):498–509.
   PubMed Web of Science ®Google Scholar
• Epstein JE, Paolino KM, Richie TL, et al. Protection against Plasmodium falciparum malaria by PfSPZ Vaccine. JCI Insight. 2017;2(1):e89154.
   PubMed Web of Science ®Google Scholar
• Wammes LJ, Hamid F, Wiria AE, et al. Regulatory T cells in human geohelminth infection suppress immune responses to BCG and Plasmodium falciparum. Eur J Immunol. 2010;40(2):437–442.
   PubMed Web of Science ®Google Scholar
• Draper SJ, Higgins MK. A new site of attack for a malaria vaccine. Nat Med. 2018;24(4):382–383.
   PubMed Web of Science ®Google Scholar
• Davies DH, Duffy P, Bodmer J-L, et al. Large screen approaches to identify novel malaria vaccine candidates. Vaccine. 2015;33(52):7496–7505.
   PubMed Web of Science ®Google Scholar
• Doolan DL, Southwood S, Freilich DA, et al. Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data. Proc Natl Acad Sci. 2003;100(17):9952–9957.
   Google Scholar
• Doolan DL, Mu Y, Unal B, et al. Profiling humoral immune responses to P. falciparum infection with protein microarrays. Proteomics. 2008;8(22):4680–4694.
   PubMed Web of Science ®Google Scholar
• Felgner PL, Roestenberg M, Liang L, et al. Pre-erythrocytic antibody profiles induced by controlled human malaria infections in healthy volunteers under chloroquine prophylaxis. Sci Rep. 2013;3:3549.
   PubMed Web of Science ®Google Scholar
• Campo JJ, Aponte JJ, Skinner J, et al. RTS,S vaccination is associated with serologic evidence of decreased exposure to Plasmodium falciparum liver- and blood-stage parasites. Mol Cell Proteomics. 2015;14(3):519–531.
   PubMed Web of Science ®Google Scholar
• Schussek S, Trieu A, Apte SH, et al. Novel Plasmodium antigens identified via genome-based antibody screen induce protection associated with polyfunctional T cell responses. Sci Rep. 2017;7(1):15053.
   PubMedGoogle Scholar
• Tuju J, Kamuyu G, Murungi LM, et al. Vaccine candidate discovery for the next generation of malaria vaccines. Immunology. 2017;152(2):195–206.
   PubMed Web of Science ®Google Scholar
• Tan J, Sack BK, Oyen D, et al. A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein. Nat Med. 2018;24(4):401–407.
   PubMed Web of Science ®Google Scholar
• Kisalu NK, Idris AH, Weidle C, et al. A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nat Med. 2018;24(4):408–416.
   PubMed Web of Science ®Google Scholar
• Holz LE, Fernandez-Ruiz D, Heath WR. Protective immunity to liver-stage malaria. Clin Transl Immunology. 2016;5(10):e105.
   PubMedGoogle Scholar
• Doolan DL, Hoffman SL. The complexity of protective immunity against liver-stage malaria. J Immunol. 2000;165(3):1453–1462.
   PubMed Web of Science ®Google Scholar
• Crompton PD, Kayala MA, Traore B, et al. A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proc Natl Acad Sci U S A. 2010;107(15):6958–6963.
   PubMed Web of Science ®Google Scholar
• Cockburn IA, Seder RA. Malaria prevention: from immunological concepts to effective vaccines and protective antibodies. Nat Immunol. 2018;19(11):1199–1211.
   PubMed Web of Science ®Google Scholar
• Stephens R, Culleton RL, Lamb TJ. The contribution of Plasmodium chabaudi to our understanding of malaria. Trends Parasitol. 2012;28(2):73–82.
   PubMed Web of Science ®Google Scholar
• Scholzen A, Sauerwein RW. Immune activation and induction of memory: lessons learned from controlled human malaria infection with Plasmodium falciparum. Parasitology. 2016;143(2):224–235.
   PubMed Web of Science ®Google Scholar
• Burel JG, Apte SH, Doolan DL. Systems approaches towards molecular profiling of human immunity. Trends Immunol. 2016;37(1):53–67.
   PubMed Web of Science ®Google Scholar
• Teirlinck AC, McCall MBB, Roestenberg M, et al. Longevity and composition of cellular immune responses following experimental Plasmodium falciparum malaria infection in humans. PLOS Pathog. 2011;7(12).
   PubMed Web of Science ®Google Scholar
• Nahrendorf W, Scholzen A, Bijker EM, et al. Memory B-cell and antibody responses induced by Plasmodium falciparum sporozoite immunization. J Infect Dis. 2014;210(12):1981–1990.
   PubMed Web of Science ®Google Scholar
• Fernandez-Ruiz D, Ng WY, Holz LE, et al. Liver-resident memory CD8(+) T cells form a front-line defense against malaria liver-stage infection. Immunity. 2016;45(4):889–902.
   PubMed Web of Science ®Google Scholar
• Tse SW, Radtke AJ, Espinosa DA, et al. The chemokine receptor CXCR6 is required for the maintenance of liver memory CD8(+) T cells specific for infectious pathogens. J Infect Dis. 2014;210(9):1508–1516.
   PubMed Web of Science ®Google Scholar
• Doll KL, Harty JT. Correlates of protective immunity following whole sporozoite vaccination against malaria. Immunol Res. 2014;59(1–3):166–176.
   PubMed Web of Science ®Google Scholar
• Draper SJ, Sack BK, King CR, et al. Malaria vaccines: recent advances and new horizons. Cell Host Microbe. 2018;24(1):43–56.
   PubMed Web of Science ®Google Scholar
• Mordmuller B, Surat G, Lagler H, et al. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature. 2017;542(7642):445–449.
   PubMed Web of Science ®Google Scholar
• Roestenberg M, McCall M, Hopman J, et al. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med. 2009;361(5):468–477.
   PubMed Web of Science ®Google Scholar
• Ishizuka AS, Lyke KE, DeZure A, et al. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat Med. 2016;22(6):614–623.
   PubMed Web of Science ®Google Scholar
• Zaidi I, Diallo H, Conteh S, et al. Gammadelta T cells are required for the induction of sterile immunity during irradiated sporozoite vaccinations. J Immunol. 2017;199(11):3781–3788.
   PubMed Web of Science ®Google Scholar
• Dunachie SJ, Walther M, Vuola JM, et al. A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. Vaccine. 2006;24(15):2850–2859.
   PubMed Web of Science ®Google Scholar
• Dunachie SJ, Walther M, Epstein JE, et al. A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infect Immun. 2006;74(10):5933–5942.
   PubMed Web of Science ®Google Scholar
• Dunachie S, Berthoud T, Hill AVS, et al. Transcriptional changes induced by candidate malaria vaccines and correlation with protection against malaria in a human challenge model. Vaccine. 2015;33(40):5321–5331.
   PubMed Web of Science ®Google Scholar
• Behet MC, Foquet L, van Gemert GJ, et al. Sporozoite immunization of human volunteers under chemoprophylaxis induces functional antibodies against pre-erythrocytic stages of Plasmodium falciparum. Malar J. 2014;13:136.
   PubMed Web of Science ®Google Scholar
• Baird JK. Age-dependent characteristics of protection v. susceptibility to Plasmodium falciparum. Ann Trop Med Parasitol. 1998;92(4):367–390.
   PubMedGoogle Scholar
• Rodriguez-Barraquer I, Arinaitwe E, Jagannathan P, et al. Quantification of anti-parasite and anti-disease immunity to malaria as a function of age and exposure. Elife. 2018;7:e35832.
   PubMed Web of Science ®Google Scholar
• Belnoue E, Fontannaz P, Rochat AF, et al. Functional limitations of plasmacytoid dendritic cells limit type I interferon, T cell responses and virus control in early life. PLoS One. 2013;8(12):e85302.
   PubMed Web of Science ®Google Scholar
• Mohr E, Siegrist CA. Vaccination in early life: standing up to the challenges. Curr Opin Immunol. 2016;41:1–8.
   PubMed Web of Science ®Google Scholar
• RTS, S Clinical Trials Partnership.. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med. 2014;11(7):e1001685.
   PubMed Web of Science ®Google Scholar
• Stoute JA, Slaoui M, Heppner DG, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S malaria vaccine evaluation group. N Engl J Med. 1997;336(2):86–91.
   PubMed Web of Science ®Google Scholar
• Regules JA, Cicatelli SB, Bennett JW, et al. Fractional third and fourth dose of RTS,S/AS01 malaria candidate vaccine: a phase 2a controlled human malaria parasite infection and immunogenicity study. J Infect Dis. 2016;214(5):762–771.
   PubMed Web of Science ®Google Scholar
• Douglas AD, Andrews L, Draper SJ, et al. Substantially reduced pre-patent parasite multiplication rates are associated with naturally acquired immunity to Plasmodium falciparum. J Infect Dis. 2011;203(9):1337–1340.
   PubMed Web of Science ®Google Scholar
• Filarsky M, Fraschka SA, Niederwieser I, et al. GDV1 induces sexual commitment of malaria parasites by antagonizing HP1-dependent gene silencing. Science. 2018;359(6381):1259–1263.
   PubMed Web of Science ®Google Scholar